Nigral endothelial dysfunction, homocysteine, and Parkinson's disease
about
Tolcapone: review of its pharmacology and use as adjunctive therapy in patients with Parkinson's diseaseHyperhomocysteinemia and neurologic disorders: a reviewHomocysteine, folate and vitamin B12 in neuropsychiatric diseases: review and treatment recommendationsStroke and idiopathic Parkinson's disease: does a shortage of dopamine offer protection against stroke?Vitamin B12-impaired metabolism produces apoptosis and Parkinson phenotype in rats expressing the transcobalamin-oleosin chimera in substantia nigra.Non-dopaminergic drug treatment of Parkinson's disease.Dopaminergic substitution in Parkinson's disease.Methylation and its role in the disposition of tanshinol, a cardiovascular carboxylic catechol from Salvia miltiorrhiza roots (Danshen).Management of L-Dopa related hyperhomocysteinemia: catechol-O-methyltransferase (COMT) inhibitors or B vitamins? Results from a review.Homocysteine Levels in Parkinson's Disease: Is Entacapone Effective?Serum Homocysteine and Folate Levels are Associated With Late-life Dementia in a Korean PopulationParkinson's Disease and Homocysteine: A Community-Based Study in a Folate and Vitamin B12 Deficient Population.Alzheimer's disease: cerebrovascular dysfunction, oxidative stress, and advanced clinical therapiesHomocysteine Level and Mechanisms of Injury in Parkinson's Disease as Related to MTHFR, MTR, and MTHFD1 Genes Polymorphisms and L-Dopa Treatment.Elevated homocysteine levels in levodopa-treated idiopathic Parkinson's disease: a meta-analysis.Molecular Effects of L-dopa Therapy in Parkinson's Disease.Hyperhomocysteinemia in patients with Parkinson's disease and relationship to vitamin B level.Adeno-associated virus-mediated gene transfer of human aromatic L-amino acid decarboxylase protects mixed striatal primary cultures from L-DOPA toxicity.123I-MIBG myocardial scintigraphy for the evaluation of Lewy body disease: are delayed images essential? Is visual assessment useful?Possible treatment concepts for the levodopa-related hyperhomocysteinemia.Clinical significance of lung iodine-123 metaiodobenzylguanidine uptake assessment in Parkinson's and heart diseases.Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients.Plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with cognitive dysfunctions.Curcumin has neuroprotection effect on homocysteine rat model of Parkinson.Plasma homocysteine levels in patients treated with levodopa: motor and cognitive associations.
P2860
Q24657680-1B14B431-AF5B-4E81-9734-380E2B517974Q28249880-EFF4FC71-1848-4C5F-916F-C0AF157F5DC1Q28259237-AAB378A6-A51A-4B0C-8745-A4F54DEFEA0DQ32052206-485052A8-C24D-4E0E-A230-9D35DE7BCC2CQ33520206-9B818D6C-29C1-4678-938E-AB396D2EFA30Q34240947-355FAC3B-1237-4C2D-B64D-C83F033BC808Q34974788-C9F3E4B0-AEA6-4A6D-96AC-F101AF1B79FAQ35578539-B7628E40-74CB-4054-B689-26942F851391Q36982674-A0D4A72C-318A-4C5B-9C1D-0EA232CEA904Q37140139-4063E06C-EB1D-4CED-8667-5D5F682D4E06Q37155647-01357E0A-2C0C-42E4-B962-7DCE46131D68Q37253963-DECD140C-3B43-412B-849A-47E56B4329DEQ37308961-CC7E88FB-B156-4A15-AA37-C7B09E109A0FQ37583408-EFB369AE-BC0B-4B32-99E6-F3F6ED445E00Q38083803-EE9B8D3F-EDD9-4B52-9857-A04A1F0CC234Q38346832-D18A9451-9FC2-4DBD-916F-2A59CFB5F7A9Q39784593-B9832B7D-52EB-42B5-B34C-0AB0F6472F43Q40433968-9873996F-2910-4CA3-B9D2-C17B00835110Q42363043-458D584C-FF01-4443-9ED0-66869DF2E8F0Q42952317-7CC6A3E0-6DFF-436D-B1D1-44384786377DQ43982303-0439E8BC-7861-442E-9B0F-E86D8A4730AFQ45076692-6F20A0A1-E3DB-4157-8717-561BD2995006Q46729832-877BD061-45C1-499F-9451-78332F170D57Q48614825-7A6B21D6-A00D-4293-AE93-B39CE4D2980FQ51907099-3D04266A-5344-4387-A4AB-41CB3497BF8F
P2860
Nigral endothelial dysfunction, homocysteine, and Parkinson's disease
description
1999 nî lūn-bûn
@nan
1999 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Nigral endothelial dysfunction, homocysteine, and Parkinson's disease
@ast
Nigral endothelial dysfunction, homocysteine, and Parkinson's disease
@en
Nigral endothelial dysfunction, homocysteine, and Parkinson's disease
@nl
type
label
Nigral endothelial dysfunction, homocysteine, and Parkinson's disease
@ast
Nigral endothelial dysfunction, homocysteine, and Parkinson's disease
@en
Nigral endothelial dysfunction, homocysteine, and Parkinson's disease
@nl
prefLabel
Nigral endothelial dysfunction, homocysteine, and Parkinson's disease
@ast
Nigral endothelial dysfunction, homocysteine, and Parkinson's disease
@en
Nigral endothelial dysfunction, homocysteine, and Parkinson's disease
@nl
P2093
P3181
P1433
P1476
Nigral endothelial dysfunction, homocysteine, and Parkinson's disease
@en
P2093
P3181
P356
10.1016/S0140-6736(99)01660-8
P407
P577
1999-07-10T00:00:00Z